排名前五的靶点	数量

GR(糖皮质激素受体)	5
30S subunit(30S核糖体亚基)	4
H1 receptor(组胺H1受体)	3
mAChRs(毒蕈碱型乙酰胆碱受体家族)	2
TPO(甲状腺过氧化物酶)	2

关联

项与津药药业股份有限公司相关的药物

Carbimazole

卡比马唑

靶点

TPO

作用机制

TPO抑制剂

在研机构

Amdipharm Mercury (Australia) Pty Ltd [+1]

原研机构

津药药业股份有限公司

在研适应症

甲状腺功能亢进症 [+1]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

澳大利亚

首次获批日期2012-05-23

Nefopam Hydrochloride

盐酸奈福泮

靶点-

作用机制-

在研机构

Maxona Pharmaceuticals, Inc.初创企业 [+1]

原研机构

津药和平（天津）制药有限公司

在研适应症

疼痛 [+2]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期1985-01-01

Betamethasone Dipropionate/Clotrimazole

倍他米松二丙酸酯/克霉唑

靶点

CYP51A1 x GR

作用机制

CYP51A1抑制剂 [+1]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1984-07-10

项与津药药业股份有限公司相关的临床试验

CTR20211217

/ CompletedN/A

QKH在空腹及餐后条件下的人体生物等效性试验

主要研究目的: 本研究考察空腹及餐后条件下单次口服由天津天药药业股份有限公司生产的QKH（受试制剂，规格：20mg）或由ShireServicesBVBA持证的参比制剂( 商品名：Plenadren®，规格：20mg）的药动学特征，比较其相对生物利用度，评价两制剂间的生物等效性，为受试制剂的注册申请提供依据。次要研究目的: 观察空腹及餐后条件下单次口服受试制剂QKH（规格：20mg）或参比制剂（商品名：Plenadren®，规格：20mg）在中国健康受试者中的安全性。

开始日期2021-06-14

申办/合作机构

津药药业股份有限公司

CTR20211107

/ CompletedN/A

活性炭阻断条件下BUD在中国健康受试者中随机、开放、两制剂、单次给药、两周期交叉的生物等效性试验

要研究目的：考察健康受试者在活性炭阻断条件下，空腹吸入天津金耀药业有限公司生产的吸入用布地奈德混悬液（受试制剂；规格：2ml:1mg；2ml/支）与AstraZeneca公司生产的吸入用布地奈德混悬液（参比制剂；规格：2ml:1mg；2ml/支；英文商品名：Pulmicort®，中文商品名：普米克令舒），比较两制剂在人体内的药代动力学参数，评价活性炭阻断条件下两种制剂在健康受试者体内的生物等效性。次要研究目的：观察受试制剂（T）和参比制剂（R）在健康受试者中的安全性。

开始日期2021-05-31

申办/合作机构

津药和平（天津）制药有限公司

CTR20210253

/ CompletedN/A

BUD在中国健康受试者中随机、开放、两制剂、单次给药、两周期交叉的生物等效性试验

主要目的：评价天津金耀药业有限公司生产的受试制剂吸入用布地奈德混悬液（规格：2ml:1mg；2ml/支）与Astrazeneca Pty Ltd生产的参比制剂吸入用布地奈德混悬液（规格：2ml:1mg；2ml/支；英文商品名：Pulmicort®，中文商品名：普米克令舒®）在中国健康成人受试者中经口腔单次雾化吸入时的生物等效性。次要目的：评价中国健康成人受试者经口腔单次雾化吸入吸入用布地奈德混悬液受试制剂和参比制剂的安全性。

开始日期2021-03-11

申办/合作机构

津药和平（天津）制药有限公司

100 项与津药药业股份有限公司相关的临床结果

登录后查看更多信息

0 项与津药药业股份有限公司相关的专利（医药）

登录后查看更多信息

项与津药药业股份有限公司相关的文献（医药）

Zhongguo Yaoye

Determination of disodium adenosine triphosphate by HPLC

作者: Cui, Fengyun ; Ren, Weichao ; Shen, Guiying

To establish an HPLC method for determining the concentration of disodium ATP in human blood plasma.The blood plasma was centrifugated after treated with trichloroacetic acid.C₁₈ column was used with methanol-potassium dihydrogen phosphate buffer solution (23:77; containing 4 mmol/L tetramethylammonium bromide) as the mobile phase.Flow rate was 1.0 mL/min, and the detection wavelength by UV was 259 nm.The linear range of concentration and peak area was 5-100 μg/mL, and the min. detection concentration was 5 μg/mL.HPLC method has a certain repeatability and accuracy under the selected operation conditions.

Chemical Industry and Engineering

Optimization of fluorination reaction in the preparation of dexamethasone acetate

作者: Wang, Fu-jun ; Zhu, Cui-hong ; Lu, Yan-chang ; Wen, Jian-ping

Fluorination reaction, a key process in the preparation of dexamethasone acetate, is optimized and the optimum conditions are obtained.The ratio of raw material to HF-DMF is 5.5:1.0, the concentration of HF-DMF is 0.6 g/mL, reaction temperature is -3° - -5° and recrystallization solvent is acetone.Under the above optimum reaction conditions, the yields of crude and purified products reach 101.0% and 75.6% resp.The purity of dexamethasone acetate is above 98.5%.

Chemical Industry and Engineering

Treatment of high content aniline wastewater by extraction

作者: Jiang, Xiao-yun ; Li, Guo-bing ; Chen, Song

By comparing of several kinds of methods for treatment of aniline wastewater, an extracting method using methylbenzene as extracting agent was proposed for the treatment of 40 g/L aniline wastewater produced in the manufacture of rubber antioxidant (RD).Based on the technol. parameters obtained from experiment, a production facility whose capacity was 20 m³/d was designed.The production showed that 98.5% of aniline was recovered.Compared with other means, the proposed extraction method has advantages such as low equipment investment, easy operation and low consumption.

项与津药药业股份有限公司相关的新闻（医药）

2023-01-04

·Business Wire

Amino Acids China E-News 2022: Real-Time Reporting, Expert Commentary and Market Trend Analysis - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Amino Acids China E-News 2022" newsletter has been added to ResearchAndMarkets.com's offering. This newsletter will help you stay ahead of the game in this fast-changing market with real-time reporting on the entire amino acid industry chain, from raw materials to end consumption. It includes breaking news from China and abroad, the latest market data (price, import & export, production, consumption, operating rates, etc.), in-depth analysis of market trends, and expert commentary from industry insiders. Key Topics Covered: Headline Editor's Note Governmental Direction Two amino acid-related draft standards open for comments Market Analysis Developments in two amino acid projects Hubei Trisun & Pingdingshan Heshengyuan: developments in glycine projects Company Dynamics Fufeng Group: rises in sales and prices of main products lead to surging H1 2022 performance Feed raw material project of Shandong Highvarve and food additives & feed additives project of Hongda Biotech Delekang Food's 120 t/a theanine project and Tianyao Holdings' amino acid project Shanghai Ajinomoto's amino acid project and Tongliao Meihua's threonine project Jirong Pharmaceutical's compound amino acids project and Jianye Amino Acid's amino acid food additives project (Phase I) Price Update The prices of major amino acid varieties in China, September 2022 Ex-works price of methionine drops for seven consecutive months Import and Export Import and export data of five amino acid varieties in China, July 2022 Import volume of methionine in Jan.-July drops YoY whereas export volume climbs YoY News in Brief Tianyao Holdings: revenue of amino acid segment for H1 2022 falls Novus International to transform its business model in China Adisseo's 180,000 t/a liquid methionine (BANC2) project goes into production First-time EIA publication of Lanzhou Jinli's 20,000 t/a sodium sarcosinate project Qinhuangdao Huaheng: first-time EIA publication of organic acids project Wilmar High Polymer Material (Lianyungang): EI report of 22,000 t/a amino acid surfactant project publicised EIA of Shandong Deep Sea's 5-ALA project publicised LHG: dual increases in operating revenue and net profit for H1 2022 Deyang Xuwei's 8,000 t/a amino acid complex compound (chelate) feed additive project MARA advocates reducing amount of soybean meal in feed and using alternatives Companies Mentioned Zhejiang Tianshun Biotechnology Co., Ltd. E'meishan Longteng Biotechnology Co., Ltd. Hubei Trisun Chemicals Co., Ltd. Pingdingshan Heshengyuan Environmental Protection New Material Co., Ltd. Shandong Asia-Pacific Highvarve Organisms Science and Technology Co., Ltd. Shandong Hongda Biotechnology Co., Ltd. Zhejiang Delekang Food Co., Ltd. Tianjin Tianyao Pharmaceuticals Co., Ltd. Shanghai Ajinomoto Amino Acid Co., Ltd. Tongliao Meihua Biological Sci-tech Co., Ltd. Shijiazhuang Jirong Pharmaceutical Co., Ltd. Shijiazhuang Jianye Amino Acid Co., Ltd. Shijiazhuang Haitian Amino Acid Co., Ltd. Zhejiang NHU Co., Ltd. Bluestar Adisseo Co., Ltd. Jinli Chemical Wool Spinning Co., Ltd. Qinhuangdao Huaheng Bioengineering Co., Ltd. Qinhuangdao Huaheng Bioengineering Co., Ltd. Anhui Huaheng Biotechnology Co., Ltd. Wilmar High Polymer Material (Lianyungang) Co., Ltd. Shandong Deep Sea Biotechnology Co., Ltd. Deyang Xuwei Biotechnology Co., Ltd. For more information about this newsletter visit https://www.researchandmarkets.com/r/t7qjmz About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

临床1期

2021-11-18

·新浪医药

天药药业子公司重酒石酸去甲肾上腺素注射液通过一致性评价_新浪医药新闻

11月18日，天药药业发布公告称，其子公司金耀药业收到国家药品监督管理局核准签发的关于重酒石酸去甲肾上腺素注射液的《药品补充申请批准通知书》，批准该药品通过仿制药质量和疗效一致性评价。重酒石酸去甲肾上腺素注射液属于《国家基本药物目录（2018年）》品种、《国家基本医疗保险、工伤保险和生育保险药品目录（2020年）》甲类品种、临床必需易短缺药品。该药品可用于某些急性低血压状态（例如嗜铬细胞切除术、交感神经切除术、脊髓灰质炎、脊髓麻醉、心肌梗死、败血症、输血和药物反应）的血压控制，作为心脏骤停和严重低血压的辅助治疗手段。对血容量不足导致的休克，本品作为急救时补充血容量的辅助治疗，以使血压回升，暂时维持脑与冠状动脉灌注，直到补充血容量治疗发生作用；也可用于心跳骤停复苏后血压维持。金耀药业重酒石酸去甲肾上腺素注射液于2002年7月取得国家药品监督管理局颁发的药品注册批件。2019年8月金耀药业向国家药品监督管理局药品审评中心提交重酒石酸去甲肾上腺素注射液一致性评价补充申请并获受理。近日，该药品通过一致性评价。截至目前，金耀药业在重酒石酸去甲肾上腺素注射液一致性评价项目上已投入研发费用约为1,000万元。目前国内市场有7家企业的重酒石酸去甲肾上腺素注射液获批上市，其中金耀药业为国内重酒石酸去甲肾上腺素注射液通过一致性评价的第二家企业。根据米内网全国放大版的医院数据（含城市公立医院、县级公立医院、城市社区医院、乡镇卫生院）显示，重酒石酸去甲肾上腺素注射液2019年销售额约10亿元，2020年销售额约12亿元。 *声明：本文由入驻新浪医药新闻作者撰写，观点仅代表作者本人，不代表新浪医药新闻立场。

一致性评价仿制药

2021-04-28

·SYNAPSE

Jinhushen Biomedical Technology Co., Ltd. made a tender offer to acquire an additional 5.29% stake in Tianjin Tianyao Pharmaceuticals Co., Ltd. for approximately CNY 200 million.

Jinhushen Biomedical Technology Co., Ltd. made a tender offer to acquire remaining 48.8% stake in Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE:600488) for CNY 2.7 billion on March 29, 2021. Jinhushen Biomedical will acquire 537.4 million shares at an offer per share of CNY 5.04. The tender offer period will be from March 31, 2021, to April 29, 2021. The pre-accepted offer cannot be withdrawn within 3 trading days before the expiry of the tender offer period which is April 27, 2021, April 28, 2021, and April 29, 2021. Changjiang Financing Services Company Limited acted as financial advisor and Grandall Law Firm acted as legal advisor for Jinhushen Biomedical Technology. Jinhushen Biomedical Technology Co., Ltd. made a tender offer to acquire an additional 5.29% stake in Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE:600488) for approximately CNY 200 million on April 29, 2021. A total of 630 accounts tendered 58.2063 million shares.

并购

100 项与津药药业股份有限公司相关的药物交易

登录后查看更多信息

100 项与津药药业股份有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年04月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

醋酸氟轻松 ( GR )	湿疹更多	批准上市
马来酸氯苯那敏 ( H1 receptor )	季节性过敏性鼻炎更多	批准上市
倍他米松二丙酸酯/克霉唑 ( CYP51A1 x GR )	外阴阴道炎更多	批准上市
硝酸毛果芸香碱 ( mAChRs )	瞳孔散大更多	批准上市
醋酸曲安奈德 ( GR )	湿疹更多	批准上市